Clinical Trial Update: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial of ruxolitinib in primary myelofibrosis and related post-PV/post-ET myelofibrosis has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (MF) | Phase 3 | Status: COMPLETED | Results posted: 2016-07-11